艾氟康唑（Efinaconzole）是由日本科研制药公司（Kaken Pharmaceutical Co.Ltd）、加拿大威朗国际制药公司（Valeant Pharmaceuticals International）开发的一种小分子三唑类抗真菌药。该药分别于2013年10月和2014年6月获准在加拿大和美国上市，用于脚趾灰指甲的治疗，该药是首个上市的外用三唑类抗真菌药。
艾氟康唑是首个外用三唑类抗真菌药，开发用于局部远端侧位甲下甲真菌（DLSO）的治疗，这是一种最为常见的甲真菌病，致病菌先侵入远端甲下甲床，甲床下角质增生、增厚，甲板可变为白色、棕色至灰褐色，表面凹凸不平，失去光泽，甲板缺失、松脆。Jublia是一种外用溶液，通过一种独特的内置用量控制型指甲刷进行涂敷，该药能很快干燥，无需出去过量的药物，同时无需顾虑系统性副作用，如药物相互作用或急性肝损伤。
艾氟康唑可用于脚趾甲灰指甲（onychomycosis）的治疗。
Topical Efinaconazole solution (0.25 to 1%) is dose-dependently effective in treating both dermatophytoses, for 10 guinea pigs with interdigital tinea pedis or tinea corporis is investigated. The follow up study performs on day-30 and day-9 posttreatment demonstrated that the relapse rates for 1% Efinaconazole-treated animals with tinea pedis and for those with tinea corporis are 20 and 30%, respectively. When a single dose of 1% Efinaconazole is applied to the back skin 48 hours before fungal inoculation, 9 of the 10 animals are protected from the dermatophytosis, suggesting that active Efinaconazole is retained in skin tissue for at least 48 hours after dosing.